PFE Dec 2024 32.000 call
| Previous Close | 0.9000 |
| Open | 0.9400 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 32.00 |
| Expire Date | 2024-12-20 |
| Day's Range | 0.8600 - 0.9500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
BloombergGSK’s New Vaccine Kept the Boss in Her Job — and an Activist at Bay
(Bloomberg) -- When Elliott Investment Management came calling for the ouster of Emma Walmsley, the chief executive officer of GSK Plc found her remedy in a product almost 60 years in the making.Most Read from BloombergHims Debuts $199 Weight-Loss Shots at 85% Discount to WegovyIran State TV Says ‘No Sign of Life’ at Helicopter Crash SiteJamie Dimon Says Succession at JPMorgan Is ‘Well on the Way’One of the Last Big Bears on Wall Street Turns Bullish on US StocksASML and TSMC Can Disable Chip Ma
Barrons.comModerna and Novavax Hope for Early Launch of This Year’s Covid-19 Shots, Despite FDA Delay
After disappointing sales for their Covid vaccines last year, drugmakers are hoping for an August rollout of the updated shot.
ZacksAstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
